ダウンロード数: 313
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
29_0365.pdf | 251.52 kB | Adobe PDF | 見る/開く |
タイトル: | 前立腺肥大症に対する脂質代謝改善剤モリステロールの効果 |
その他のタイトル: | Effect of Moristerol (anti-cholesterolemic agent) on benign prostatic hypertrophy |
著者: | 田島, 惇 大見, 嘉郎 阿曽, 佳郎 太田, 信隆 牛山, 知己 畑, 昌宏 藤井, 一彦 増田, 宏昭 |
著者名の別形: | Tajima, Atsushi Ohmi, Yoshio Aso, Yoshio Ohta, Nobutaka Ushiyama, Tomomi Hata, Masahiro Fujii, Kazuhiko Masuda, Hiroaki |
キーワード: | Anticholesteremic Agents/therapeutic use Drug Evaluation Humans Lipids/blood Male Phytosterols/therapeutic use Prostatic Hyperplasia/blood/drug therapy |
発行日: | Mar-1983 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 29 |
号: | 3 |
開始ページ: | 365 |
終了ページ: | 369 |
抄録: | Moristerol was orally administered in 20 cases of benign prostatic hypertrophy. One capsule of Moristerol contained 200 mg of soysterol . In all the cases, 9 capsules of Moristerol were given per day in three divided doses for 6 weeks. Clinical improvement was observed in 11 of the 20 cases (55%). It consisted mainly of subjective complaints such as improvement of dysuria, narrow and weak urinary stream and feeling of incomplete voiding. As objective findings, a statistically significant decrease of residual urine volume was noted after treatment, although shrinkage of the enlarged prostate was not clear upon palpation or roentgenography. In addition to the improvement of symptoms, serum lipid peroxide which might be considered to be a provocative cause of benign prostatic hypertrophy, was also significantly decreased by Moristerol administration. No marked side effects were seen in this study. |
URI: | http://hdl.handle.net/2433/120129 |
PubMed ID: | 6203383 |
出現コレクション: | Vol.29 No.3 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。